Eledon reports 24-month Phase 2 BESTOW extension data showing higher eGFR with tegoprubart vs tacrolimus in kidney transplant patients

PUBT · 2d ago
Eledon reports 24-month Phase 2 BESTOW extension data showing higher eGFR with tegoprubart vs tacrolimus in kidney transplant patients
  • Eledon disclosed updated long-term Phase 2 BESTOW extension results, already presented at The Transplantation Society meeting in Sydney.
  • Tegoprubart patients showed better sustained kidney graft function than tacrolimus, supporting a potential shift away from calcineurin-based regimens.
  • Rejection events stopped after the early post-transplant period in the tegoprubart arm, while the tacrolimus arm recorded additional cases.
  • FDA granted Fast Track designation for tegoprubart in kidney transplant rejection prevention, strengthening the regulatory path toward late-stage development.
  • A global Phase 3 LEGACY trial is slated to start in Q4 2026, targeting about 600 patients with a 12-month composite efficacy endpoint.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Eledon Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609220700PRIMZONEFULLFEED9831159) on September 22, 2026, and is solely responsible for the information contained therein.